This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?
by Kinjel Shah
JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine sales.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
What's Fueling Tempus AI's Explosive Sales Growth?
by Sridatri Sarkar
TEM's Q1 revenues jump 75.4%, powered by soaring genomics sales, strategic deals and new test launches.
Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Astrazeneca (AZN) reached $71.46 at the closing of the latest trading day, reflecting a +2.26% change compared to its last close.
Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
by Kinjel Shah
PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
by Moumi Mondal
TEM is scaling fast; Data and Services revenues soar 43%, fueled by big-name pharma and AI model deals.
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
by Kanishka Das
Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.
Is Astrazeneca (AZN) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?
by Kinjel Shah
SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
by Zacks Equity Research
FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
by Sundeep Ganoria
ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?
by Urmimala Biswas
GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
by Kinjel Shah
PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance.
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?
by Zacks Equity Research
Merck's Gardasil sales decline due to weak demand trends in China, with new launches expected to offset the downside.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Astrazeneca (AZN) concluded the recent trading session at $73.55, signifying a -1.17% move from its prior day's close.
Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach
by Moumi Mondal
TEM expands major partnerships with AZN, ILMN, and PSNL, fueling AI-driven R&D and widening its precision medicine reach.
The Zacks Analyst Blog Highlights Microsoft, AstraZeneca and BlackRock, Taylor Devices and Geospace Technologies
by Zacks Equity Research
MSFT, AZN, and BLK lead Zacks' top stock picks, while TAYD and GEOS show resilience despite microcap market pressures.
Top Stock Reports for Microsoft, AstraZeneca & BlackRock
by Mark Vickery
MSFT, AZN, and BLK earn praise in fresh Zacks reports, with AI, pharma pipelines, and AUM growth fueling long-term outlooks.
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds
by Kinjel Shah
PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $73.83, representing a +1.12% change from its previous close.
Is IonQ a Better Quantum Computing Stock to Buy Than D-Wave?
by Tirthankar Chakraborty
QTUM soars 42% in a year, led by IONQ and QBTS. Which quantum stock is the better buy?